Back to School: How biopharma can reboot drug development. Access exclusive analysis here
ENZN reported an adjusted net loss of $113,000 for the first quarter of fiscal 2005. This
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury